anti-Raf-1, pAb

CHF 315.00
In stock
YIF-LF-PA0195100 µlCHF 315.00
More Information
Product Details
Synonyms RAF; cRaf; RAF1; Raf-1; EC=; Proto-Oncogene c-RAF; RAF Proto-Oncogene Serine/Threonine-Protein Kinase
Product Type Polyclonal Antibody
Immunogen/Antigen Synthetic peptide.

Western Blot (1:2,000)

Crossreactivity Human
Purity Detail Protein A purified.
Concentration 1 mg/ml
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

RAF is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. The mammalian Raf family of serine/threonine kinases consists of three highly conserved members: A-Raf, B-Raf, and Raf-1 (or c-Raf-1). Each isoform has three conserved regions in common: CR1, CR2, and CR3. Raf isoforms vary in their cell-specific expression and potency of kinase activity. Cytosolic C-Raf ubiquitously expressed in adult tissues, with highest expression in muscle, cerebellum, and fetal brain. Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites. Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to subsequent activation events. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. Part of the Ras-dependent signaling pathway from receptors to the nucleus. Protects cells from apoptosis mediated by STK3.

Product References

1) Fischer A et al., (2007) J Biol Chem 282(36):26503-16. (General)
2) Sridhar SS et al., (2005) Mol Cancer Ther 4(4):677-85. (General)
3) Balan V et al., (2006) Mol Biol Cell 17(3):1141-53. (General)
4) Dougherty MK et al., (2005) Mol Cell 17:215-224. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.